April 17 (Reuters) - VBI Vaccines Inc:
* VBI VACCINES ANNOUNCES POSITIVE DSMB REVIEW IN PHASE 1/2A STUDY OF VBI-1901 IN RECURRENT GLIOBLASTOMA (GBM) PATIENTS
* VBI VACCINES INC - INDEPENDENT DATA AND SAFETY MONITORING BOARD UNANIMOUSLY RECOMMENDS CONTINUATION OF STUDY WITHOUT MODIFICATION
* VBI VACCINES INC - INITIATED ENROLLMENT IN INTERMEDIATE-DOSE ARM OF DOSE-ESCALATION PHASE OF STUDY Source text for Eikon: Further company coverage: